Transcode Therapeutics (RNAZ) Accounts Payables (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Accounts Payables came in at $5.3 million in Q1 2026, up 110.92% YoY from $2.5 million in Q1 2025, and up 51.49% on a QoQ basis from $3.5 million in Q4 2025.
Transcode Therapeutics (RNAZ) Accounts Payables (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Accounts Payables data on file, last reported at $5.3 million in Q1 2026.
- Quarterly Accounts Payables rose 110.92% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 110.92% YoY) and the FY2025 annual result came in at $3.5 million, up 29.03% from the prior year.
- Accounts Payables advanced to $5.3 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.3 million in Q1 2026 to a low of $1.6 million in Q2 2025.
- A 5-year average of $3.2 million and a median of $3.0 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables soared 177.11% — and 2024, when it sank 58.52%.
- Tracing RNAZ's Accounts Payables over 5 years: stood at $4.3 million in 2022, then fell by 29.81% to $3.1 million in 2023, then declined by 11.25% to $2.7 million in 2024, then climbed by 29.03% to $3.5 million in 2025, then surged by 51.49% to $5.3 million in 2026.
- The last three Accounts Payables figures came in at $5.3 million (Q1 2026), $3.5 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.29 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Sep 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 3.28 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 5.06 Mn |
| Dec 31, 2022 | 4.35 Mn |
| Sep 30, 2022 | 3.75 Mn |
| Jun 30, 2022 | 1.70 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 1.98 Mn |
| Jun 30, 2021 | 1.22 Mn |